Comparing the current results to its competitors, Abivax Sa reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, slower than the combined decrease of the ABVX's competitors by -0.11 %, recorded in the same quarter.
Abivax Sa's Comment on Competition and Industry Peers
The chronic inflammatory disease market is primarily occupied by large pharmaceutical companies including AbbVie, Johnson & Johnson, Takeda, Pfizer, and Eli Lilly. Potential future competitors include Merck, Roche, and Teva/Sanofi, following their recent acquisitions of TL1A molecules. Multiple companies are developing new treatments for inflammatory bowel disease (IBD), focusing on therapies that are more effective, better tolerated, and available in practical formulations, particularly orally administered small molecules as alternatives to injectable or intravenous monoclonal antibodies. Current and investigational treatments target mechanisms such as TNF-alpha inhibition, IL-12/23 inhibition, anti-integrin antibodies, IL-23 inhibition, and JAK inhibition.
October 3, 2024
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by inflammation of the colon, resulting in a range of distressing symptoms. Current treatment options include aminosalicylates, corticosteroids, immunomodulators, and biologics; however, there remains a need for novel therapeutic agents that can effectively manage moderate to severe forms of the disease with a better safety profile. Abivax, a biopharmaceutical company, has been investigating the efficacy and safety of obefazimod, a once-daily oral treatment with a mechanism that modulates immune response, in patients with moderate to severe UC over an extended period. Study Overview Abivax s interim analysis reports outcomes from a...
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
The business model of Innovation1 Biotech Inc involves developing and commercializing innovative biotechnological products and solutions for various industries. The company focuses on research, development, and manufacturing, aiming to provide cutting-edge biotech solutions that meet the needs of diverse markets.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Sources:
Abivax Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Abivax Sa versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
